Mondelez International, Inc. · MDLZ · FY2025 Q1 · Calendar Q2 2025
Mondelez Maintains Guidance as Pricing Offsets Cocoa Pressure
The quarter supports a cautiously constructive view of Mondelez's operating trajectory: pricing, share gains, product innovation and emerging-market distribution offset cocoa inflation and US biscuit softness, but the durability of demand and margins remains unproven.
Earnings scorecard
Reported versus consensusMarket reaction
event-close to next-session closeAsk FN2 about MDLZ FY2025 Q1
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management moved from a prior-quarter lowered guidance sentiment to maintained FY25 guidance. Current analysis emphasizes 3.1% organic revenue growth, chocolate share gains, 3.9% emerging-market growth and continued US biscuit softness tied to consumer confidence and retail destocking.
Guidance delta
Management maintained FY25 guidance, contrasting with the prior quarter's lowered guidance sentiment.
Key takeaways
- Organic revenue grew 3.1%, supported by chocolate pricing despite record cocoa inflation.
- Chocolate share gains and new products, including Cadbury Biscoff, supported momentum.
- US biscuit volumes softened amid consumer confidence concerns and retail destocking.
- Emerging markets grew 3.9%, with distribution expanded by more than 100,000 stores.
- Management maintained FY25 guidance and highlighted continued pricing and capital-allocation discipline.
Management priorities
- Execute pricing and revenue-growth-management initiatives
- Launch and expand new chocolate and biscuit products
- Extend distribution in emerging markets
- Continue Cocoa Life and sustainability investments
- Maintain disciplined capital allocation and share repurchases
Follow MDLZ with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 16, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 5, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 30, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 29, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 29, 2026 |
| BNP Paribas | Outperform | Outperform | Maintain | Jul 29, 2026 |
| UBS | Neutral | Neutral | Maintain | Apr 29, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 29, 2026 |
| B of A Securities | Buy | Buy | Maintain | Apr 10, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Mar 30, 2026 |
| Rothschild & Co | Neutral | Buy | Downgrade | Mar 25, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Mar 16, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Feb 18, 2026 |
| DA Davidson | Neutral | Neutral | Maintain | Feb 9, 2026 |
| Stifel | Buy | Buy | Maintain | Feb 4, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 4, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jan 8, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 29, 2025 |
| Jefferies | Buy | Hold | Upgrade | Jul 17, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 6, 2025 |
| Citigroup | Buy | Buy | Maintain | Jan 8, 2025 |
| Argus Research | Buy | Hold | Upgrade | Nov 28, 2023 |
| Exane BNP Paribas | Outperform | Neutral | Upgrade | Oct 17, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 6, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Feb 1, 2023 |
| BMO Capital | Outperform | Outperform | Maintain | Jan 31, 2022 |
| Seaport Global | Buy | Buy | Maintain | Jul 28, 2020 |
| Berenberg | Buy | Hold | Upgrade | Jun 15, 2020 |
| Guggenheim | Buy | Buy | Maintain | Apr 29, 2020 |
| Buckingham Research | Buy | Buy | Maintain | Feb 11, 2020 |
| Buckingham | Buy | Buy | Maintain | Feb 11, 2020 |
| Stifel Nicolaus | Hold | Hold | Maintain | Jun 17, 2019 |
| DZ Bank | Buy | Hold | Upgrade | Jul 27, 2018 |
| Societe Generale | Buy | Hold | Upgrade | Feb 2, 2018 |
| Bank of America | Buy | Buy | Maintain | Feb 1, 2018 |
| PiperJaffray | Overweight | Neutral | Upgrade | Jul 25, 2017 |
| Susquehanna | Neutral | Positive | Downgrade | Feb 8, 2017 |
| Canaccord Genuity | Buy | Hold | Upgrade | Feb 4, 2016 |
| CLSA | Outperform | Buy | Maintain | Aug 6, 2015 |
| Nomura | Sell | Reduce | Maintain | Apr 9, 2014 |
| First Global | Outperform | Outperform | Maintain | Dec 11, 2013 |
| Credit Agricole | Underperform | Outperform | Downgrade | May 8, 2013 |
| Janney Capital | Neutral | Neutral | Maintain | Oct 12, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $63.92. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $70 | $64.99 | +9.5% | Jul 30, 2026 |
| UBS | Peter Grom | $68 | $65.53 | +6.4% | Jul 29, 2026 |
| Coker Palmer | Thomas Palmer | $72 | $62.48 | +12.6% | Jul 29, 2026 |
| BTIG | Rob Dickerson | $73 | $62.48 | +14.2% | Jul 29, 2026 |
| Jefferies | Scott Marks | $73 | $62.48 | +14.2% | Jul 29, 2026 |
| Piper Sandler | Michael Lavery | $65 | $61.5 | +1.7% | Apr 29, 2026 |
| Evercore ISI | David Palmer | $71 | $61.45 | +11.1% | Apr 29, 2026 |
| UBS | Analyst unavailable | $64 | $58.54 | +0.1% | Apr 29, 2026 |
| Barclays | Andrew Lazar | $68 | $58.54 | +6.4% | Apr 29, 2026 |
| BTIG | Rob Dickerson | $70 | $57.68 | +9.5% | Apr 13, 2026 |
| Bernstein | Analyst unavailable | $73 | $59.86 | +14.2% | Feb 18, 2026 |
| D.A. Davidson | Analyst unavailable | $64 | $59.52 | +0.1% | Feb 9, 2026 |
| D.A. Davidson | Brian Holland | $62 | $59.2 | -3.0% | Feb 4, 2026 |
| Stifel Nicolaus | Analyst unavailable | $68 | $59.94 | +6.4% | Feb 4, 2026 |
| Morgan Stanley | Megan Alexander Clapp | $66 | $59.47 | +3.2% | Feb 4, 2026 |
| Piper Sandler | Michael Lavery | $64 | $59.47 | +0.1% | Feb 4, 2026 |
| Wells Fargo | Analyst unavailable | $65 | $59.47 | +1.7% | Feb 4, 2026 |
| UBS | Analyst unavailable | $63 | $59.47 | -1.4% | Feb 4, 2026 |
| Morgan Stanley | Analyst unavailable | $65 | $59.15 | +1.7% | Jan 28, 2026 |
| Deutsche Bank | Analyst unavailable | $61 | $58.4 | -4.6% | Jan 26, 2026 |
| Coker Palmer | Thomas Palmer | $69 | $57.34 | +7.9% | Jan 21, 2026 |
| UBS | Analyst unavailable | $60 | $56.82 | -6.1% | Jan 14, 2026 |
| Mizuho Securities | Analyst unavailable | $67 | $51.51 | +4.8% | Jan 8, 2026 |
| Wells Fargo | Chris Carey | $62 | $53.28 | -3.0% | Jan 5, 2026 |
| Piper Sandler | Analyst unavailable | $62 | $55.75 | -3.0% | Nov 21, 2025 |
| Barclays | Analyst unavailable | $67 | $57.85 | +4.8% | Oct 30, 2025 |
| RBC Capital | Nik Modi | $67 | $60.21 | +4.8% | Oct 29, 2025 |
| Stifel Nicolaus | Analyst unavailable | $70 | $58.78 | +9.5% | Oct 29, 2025 |
| Mizuho Securities | Analyst unavailable | $70 | $60.21 | +9.5% | Oct 29, 2025 |
| Bernstein | Alexia Howard | $84 | $60.21 | +31.4% | Oct 29, 2025 |
| Morgan Stanley | Megan Alexander Clapp | $68 | $57.87 | +6.4% | Oct 29, 2025 |
| Piper Sandler | Analyst unavailable | $63 | $60.21 | -1.4% | Oct 29, 2025 |
| Wells Fargo | Analyst unavailable | $72 | $60.21 | +12.6% | Oct 29, 2025 |
| Mizuho Securities | Analyst unavailable | $73 | $61.65 | +14.2% | Oct 28, 2025 |
| UBS | Peter Grom | $65 | $62.6 | +1.7% | Oct 8, 2025 |
| Morgan Stanley | Analyst unavailable | $71 | $61.99 | +11.1% | Oct 6, 2025 |
| Berenberg Bank | Analyst unavailable | $70 | $63.17 | +9.5% | Oct 2, 2025 |
| Evercore ISI | Analyst unavailable | $72 | $62.56 | +12.6% | Sep 26, 2025 |
| Barclays | Analyst unavailable | $77 | $64.56 | +20.5% | Jul 31, 2025 |
| Bernstein | Analyst unavailable | $88 | $65.1 | +37.7% | Jul 30, 2025 |
| Piper Sandler | Analyst unavailable | $59 | $67.5 | -7.7% | Mar 27, 2025 |
| Morgan Stanley | Analyst unavailable | $69 | $64.95 | +7.9% | Mar 24, 2025 |
| Wells Fargo | Chris Carey | $61 | $58.29 | -4.6% | Jan 8, 2025 |
| Piper Sandler | Michael Lavery | $84 | $68.35 | +31.4% | Oct 30, 2024 |
| Wells Fargo | Chris Carey | $78 | $69.15 | +22.0% | Oct 30, 2024 |
| Piper Sandler | Michael Lavery | $74 | $71.35 | +15.8% | Oct 23, 2024 |
| Bank of America Securities | Peter Galbo | $84 | $70.53 | +31.4% | Oct 15, 2024 |
| Piper Sandler | Michael Lavery | $76 | $69.16 | +18.9% | Aug 9, 2024 |
| D.A. Davidson | Brian Holland | $75 | $67.05 | +17.3% | Jul 31, 2024 |
| Piper Sandler | Michael Lavery | $78 | $67.98 | +22.0% | Jun 5, 2024 |
| Jefferies | Rob Dickerson | $78 | $67.89 | +22.0% | May 31, 2024 |
| Piper Sandler | Michael Lavery | $81 | $67.6 | +26.7% | Apr 9, 2024 |
| RBC Capital | Nik Modi | $83 | $71.48 | +29.8% | Nov 27, 2023 |
| Morgan Stanley | Pamela Kaufman | $74 | $71.49 | +15.8% | Nov 24, 2023 |
| Cowen & Co. | Analyst unavailable | $75 | $65.92 | +17.3% | Feb 6, 2023 |
| Barclays | Analyst unavailable | $72 | $66.73 | +12.6% | Feb 2, 2023 |
| Wells Fargo | Analyst unavailable | $77 | $65.78 | +20.5% | Feb 1, 2023 |
| Credit Suisse | Analyst unavailable | $76 | $65.44 | +18.9% | Feb 1, 2023 |
| Piper Sandler | Analyst unavailable | $80 | $65.44 | +25.1% | Feb 1, 2023 |
| Morgan Stanley | Pamela Kaufman | $75 | $66.09 | +17.3% | Dec 20, 2022 |
| Piper Sandler | Analyst unavailable | $77 | $67.26 | +20.5% | Dec 15, 2022 |
| UBS | Analyst unavailable | $71 | $68.03 | +11.1% | Dec 8, 2022 |
| Deutsche Bank | Analyst unavailable | $75 | $67.32 | +17.3% | Dec 6, 2022 |
| BNP Paribas | Analyst unavailable | $68 | $64.1 | +6.4% | Nov 15, 2022 |
| Credit Suisse | Robert Moskow | $67 | $58.1 | +4.8% | Oct 18, 2022 |
| Mizuho Securities | Analyst unavailable | $75 | $64.68 | +17.3% | Apr 27, 2022 |
| Morgan Stanley | Pamela Kaufman | $70 | $65.78 | +9.5% | Apr 26, 2022 |
| Jefferies | Robert Dickerson | $76 | $67.1 | +18.9% | Jan 27, 2022 |
| Mizuho Securities | John Baumgartner | $77 | $66.25 | +20.5% | Jan 26, 2022 |
| Deutsche Bank | Stephen Powers | $73 | $67.38 | +14.2% | Jan 20, 2022 |
| Morgan Stanley | Pamela Kaufman | $73 | $68.1 | +14.2% | Jan 16, 2022 |
| Bank of America Securities | Bryan Spillane | $75 | $67.04 | +17.3% | Jan 5, 2022 |
| Goldman Sachs | Jason English | $71 | $62.2 | +11.1% | Jul 30, 2021 |
| Guggenheim | Laurent Grandet | $66 | $62.34 | +3.2% | Jul 28, 2021 |
| Stifel Nicolaus | Christopher Growe | $67 | $59.56 | +4.8% | Apr 28, 2021 |
| Credit Suisse | Robert Moskow | $68 | $59.56 | +6.4% | Apr 28, 2021 |
Track every rating change on MDLZ the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMondelez International, Inc. operates as a prominent global entity in the snack and beverage sector, focusing on the production, promotion, and distribution of a wide array of food items. Its extensive reach spans multiple continents, including North America, Latin America, Asia, the Middle East, Africa, and Europe. The company's diverse product portfolio encompasses biscuits (such as cookies, crackers, and various savory snacks), chocolates, chewing gums, candies, as well as selection of cheese and general grocery products, and powdered beverage mixes.…
Historical context
All MDLZ earningsLatest beats and misses
Who reports nextBeat on EPS
Get the MDLZ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-15T00:03:42.498162+00:00
- Polygon adjusted daily market bars · 2026-10-16T11:40:44.043425+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-16T11:40:44.040470+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-16. For educational purposes only; not investment advice.